Pull up the NMPA’s Breakthrough Therapy Drug criteria and read the bar: drugs must address serious or life-threatening diseases where clinical evidence suggests “substantial improvement” over existing therapies. Now consider that MSS/pMMR metastatic colorectal cancer — the microsatellite stable subtype representing roughly 85% of all metastatic CRC cases — has been the graveyard of checkpoint inhibitor ambitions for a decade. Every major PD-1 sponsor has run into this wall. On May 10, 2026, Innovent walked through it.
IBI363, Innovent’s PD-1/IL-2α-bias bispecific fusion protein, received its third NMPA Breakthrough Therapy Designation — this time for advanced MSS/pMMR colorectal cancer in combination with bevacizumab. The first designation covered unresectable locally advanced or metastatic mucosal or acral melanoma in the frontline setting. The second followed. Now a third, in an indication that the rest of the oncology world has essentially written off for immunotherapy.
Three designations for three distinct indications, all pointing at the same molecule. That pattern doesn’t happen by accident.
What the Checkpoint Crowd Missed
The old logic was seductive: MSS colorectal cancer lacks the mutational burden that makes tumors visible to T cells, so PD-1 blockade alone can’t do meaningful work. That logic held up experimentally — and commercially. Merck’s pembrolizumab and Bristol Myers Squibb’s nivolumab both found their CRC homes in the MSI-H minority, leaving the MSS majority without an immunotherapy option. The market assumed the biology was simply unfavorable and moved on to VEGF combinations, KRAS inhibitors, and antibody-drug conjugates.
IBI363’s mechanism challenges that assumption at its foundation. By fusing PD-1 blockade with an IL-2 signal biased toward the alpha subunit — preferentially activating tumor-infiltrating lymphocytes rather than peripheral regulatory T cells — the construct attempts to solve the cold tumor problem from the inside rather than trying to heat it from outside. Phase 1 data presented at ASCO showed encouraging efficacy in immunotherapy-treated acral and mucosal melanoma patients, a population historically resistant to salvage immunotherapy. The NMPA’s willingness to grant a third designation, in a notoriously immune-excluded tumor type, tells you the agency saw something in the early CRC data worth accelerating.
And the NMPA’s threshold here is not trivial. China’s CDE approved 91 of 337 BTD applications in 2024 — a 27% approval rate. This is not a rubber stamp. Three designations for a single asset across genuinely distinct oncologic settings is a regulatory signal that the platform biology is doing real work, not just generating promising waterfall plots in favorable patient selection.
Who Holds the Upside — and Who Gets Exposed
Innovent’s commercial position in China looks structurally stronger than the headline suggests. The company already has NMPA-approved products on the market — including Pecondle (picankibart), the first homegrown IL-23p19 inhibitor approved in China — which means it has commercial infrastructure, payer relationships, and KOL engagement already active. Stacking a potential IBI363 approval onto an existing commercial engine is a fundamentally different launch math than a pure biotech entering China cold.
The more uncomfortable calculation sits inside the Western oncology majors. Merck has peak sales estimates for pembrolizumab in CRC anchored entirely to the MSI-H population, which represents a fraction of the addressable disease burden. If IBI363 demonstrates durable responses in MSS/pMMR CRC at scale, it doesn’t just compete in China — it validates a mechanism that every large-cap PD-1 sponsor will need to license, build, or buy. The BD&L implications are significant. A platform that can reactivate immune responses in cold tumors sits upstream of nearly every immuno-oncology combination strategy currently in Phase 2 or 3 development globally.
The losers in the near term are the VEGF-combination and KRAS-inhibitor players who have been positioning MSS CRC as their exclusive commercial territory. Amgen’s sotorasib combinations and Mirati’s adagrasib franchise both carry MSS CRC as a strategic growth indication. A credible immunotherapy entrant — particularly one backed by three regulatory designations and a biologic rationale for cold tumor penetration — compresses the commercial runway those assets were counting on.
There’s also a partnership valuation story here that the market is under-pricing. Phase 1 data from NCT05460767 presented at ASCO 2024 showed IBI363 monotherapy generating responses in a heavily pretreated population. Add the bevacizumab combination data that supported the third BTD, and you have a two-modality development program with regulatory validation in three indications. For a Western partner evaluating a China-anchored oncology asset, the PTRS on a deal just moved materially.
The Move Decision-Makers Need to Make Now
If you are running BD strategy at a mid-to-large oncology company with a China development gap, the clock on a reasonable IBI363 licensing conversation started running on May 10. Innovent has now demonstrated that this platform earns accelerated designation across tumor types — melanoma, and now MSS CRC — which means the licensing ask will only get more expensive as Phase 2 readouts arrive. The combination bevacizumab data already exists. The regulatory designation already exists. The negotiating leverage is moving in one direction.
Watch the next ASCO or ESMO abstract submission cycle for combination efficacy data in the MSS CRC cohort. Response rates above 15% in this indication — historically near zero for checkpoint monotherapy — would reframe the entire competitive map for second-line colorectal cancer treatment. That number, when it arrives, won’t stay inside a conference hall.
References
- PR Newswire — “Innovent Announces IBI363 Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer”
- NMPA — “Provisions for Drug Registration: Breakthrough Therapy Drug Procedure Criteria”
- CISEMA — “NMPA CDE 2024 Breakthrough Therapy Designation Approval Data”
- ASCO 2024 — “IBI363 Phase 1 Efficacy Data in Acral and Mucosal Melanoma”
- ASCO 2024 — “IBI363 Monotherapy Phase 1 Study Data”
- Pharmaphorum — “Innovent receives NMPA approval for Pecondle (picankibart), China’s first homegrown IL-23p19 drug”
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
